Po-Hsien Hsu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Po-Hsien Hsu has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Chao-Chin Li
Institute of Cellular and Organismic Biology, Academia Sinica, Nankang, Taipei, 115, Taiwan
1 shared publication- Che Ma
Genomics Research Center, Academia Sinica
1 shared publication - Chih-Cheng Cheng
Division of General Surgery, Department of Surgery, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan
1 shared publication Chu-Yi Hsieh
Marine Research Station, Institute of Cellular and Organismic Biology, Academia Sinica, 23-10, Dahuen Rd., Jiaushi, Ilan, 262, Taiwan
1 shared publication- Hong Thuy Vy Nguyen
Genomics Research Center, Academia Sinica, Taipei, Taiwan
1 shared publication - Jyh-Yih Chen
Marine Research Station, Institute of Cellular and Organismic Biology, Academia Sinica, 23-10 Dahuen Road, Jiaushi, Ilan, 262, Taiwan.
1 shared publication
Latest Publications
- Open Access
- 30 April 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (18)
Broad neutralization of influenza B hemagglutinin antibodies via receptor mimicry and glycan engagement
Influenza B virus contributes to seasonal influenza epidemics and causes global morbidity and mortality. The two antigenically distinct lineages, Victoria and Yamagata, cocirculate within the population and are subject to ongoing antigenic drift. In this study, we report the isolation of cross-lineage neutralizing anti-influenza B hemagglutinin (HA) monoclonal antibodies, exhibiting hemagglutination-inhibition activities, from vaccinated adult donors. While some antibodies exhibit reduced activities against recently emerged antigenic variants, BP-1A and BO-6B demonstrate broad neutralization across influenza B viruses isolated over the past two decades and confer protection in mice against lethal challenge from both lineages. Structural analysis of the antibody Fab domains in complex with HA reveals two distinct molecular binding modes: BP-1A uses a long heavy chain CDR3 loop that mimics the ligand to target the receptor-binding site, while BO-6B engages a conserved cleft on the surface of vestigial esterase subdomain through key interactions with glycan moieties. These findings elucidate the molecular basis for broad neutralization by human anti-influenza B HA antibodies and provide insights that may guide the development of immunotherapeutics and rational vaccine design.
- 30 April 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (18)
Open AccessBroad neutralization of influenza B hemagglutinin antibodies via receptor mimicry and glycan engagement
Influenza B virus contributes to seasonal influenza epidemics and causes global morbidity and mortality. The two antigenically distinct lineages, Victoria and Yamagata, cocirculate within the population and are subject to ongoing antigenic drift. In this study, we report the isolation of cross-lineage neutralizing anti-influenza B hemagglutinin (HA) monoclonal antibodies, exhibiting hemagglutination-inhibition activities, from vaccinated adult donors. While some antibodies exhibit reduced activities against recently emerged antigenic variants, BP-1A and BO-6B demonstrate broad neutralization across influenza B viruses isolated over the past two decades and confer protection in mice against lethal challenge from both lineages. Structural analysis of the antibody Fab domains in complex with HA reveals two distinct molecular binding modes: BP-1A uses a long heavy chain CDR3 loop that mimics the ligand to target the receptor-binding site, while BO-6B engages a conserved cleft on the surface of vestigial esterase subdomain through key interactions with glycan moieties. These findings elucidate the molecular basis for broad neutralization by human anti-influenza B HA antibodies and provide insights that may guide the development of immunotherapeutics and rational vaccine design.
- 18 January 2023
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 249, 115131
Strategic modification of low-activity natural antimicrobial peptides confers antibacterial potential in vitro and in vivo
- 18 January 2023
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 249, 115131
Strategic modification of low-activity natural antimicrobial peptides confers antibacterial potential in vitro and in vivo